Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Bleomycin-induced pulmonary fibrosis is known to be associated with the increased activity of two gelatinases, matrix metalloproteinase (MMP)-2 and MMP-9, in bronchoalveolar lavage (BAL). This study has investigated the effect of a synthetic inhibitor of MMP, batimastat, on the development of pulmonary fibrosis induced by bleomycin administration in mice. Animals were intranasally instilled with saline or bleomycin (0.5 mg in 100 microl per mouse). Batimastat (30 mg/kg) or vehicle alone was administered by intraperitoneal injection 24 h and 1 h before saline or bleomycin instillation, and then daily at the same dosage until the end of the study. Fifteen days after bleomycin administration, BAL was performed and the lung was removed. Treatment of mice with batimastat significantly reduced bleomycin-induced lung fibrosis, as shown in the lung by histopathological examination and by a decrease in hydroxyproline levels. Batimastat also prevented the increase in BAL macrophage and lymphocyte numbers, whereas it did not show any effect on the increased expression of active transforming growth factor-beta (TGF-beta) in BAL. Batimastat treatment was effective in reducing MMP-2 and MMP-9 activity as well as the tissue inhibitor of metalloproteinase-1 (TIMP-1) level in BAL. These results suggest that administration of the MMP inhibitor batimastat is useful in preventing experimental pulmonary fibrosis induced by bleomycin and raises the possibility of a therapeutic approach to human pulmonary fibrotic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Khalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505
Cited by
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
Metalloproteinases and their inhibitors: Regulators of wound healing
Gill, S. E., & Parks, W. C. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.10.024 · Cited by 742
Matrix Metalloproteinase-9 in Lung Remodeling
Atkinson, J. J., & Senior, R. M. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2002-0166tr · Cited by 587
Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis
Craig, V. J., Zhang, L., Hagood, J. S., & Owen, C. A. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0020tr · Cited by 507
Matrix Metalloproteinases in Lung: Multiple, Multifarious, and Multifaceted
Greenlee, K. J., Werb, Z., & Kheradmand, F. (2007) · Physiological Reviews · doi:10.1152/physrev.00022.2006 · Cited by 474
Immune mechanisms in pulmonary fibrosis
Kolahian, S., Fernandez, I. E., Eickelberg, O., & Hartl, D. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0121tr · Cited by 349
Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF-β-Mediated Pulmonary Fibrosis
Bonniaud, P., Kolb, M., Galt, T., Robertson, J., Robbins, C., Stampfli, M., Lavery, C., Margetts, P. J., Roberts, A. B., & Gauldie, J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2099 · Cited by 382
Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT?
Radisky, D. C., Kenny, P. A., & Bissell, M. J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21186 · Cited by 344
Morry, J., Ngamcherdtrakul, W., & Yantasee, W. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.011 · Cited by 333
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
Lanone, S., Zheng, T., Zhu, Z., Liu, W., Lee, C. G., Ma, B., Chen, Q., Homer, R. J., Wang, J., Rabach, L. A., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14136 · Cited by 299
Robert, S., Gicquel, T., Victoni, T., Valença, S., Barreto, E., Bailly-Maître, B., Boichot, E., & Lagente, V. (2016) · Bioscience Reports · doi:10.1042/bsr20160107 · Cited by 190
Self-citationManoury, B., Nenan, S., Leclerc, O., Guenon, I., Boichot, E., Planquois, J.-M., Bertrand, C. P., & Lagente, V. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-11 · Cited by 186
Self-citation
Metadata
- Authors
- Corbel, M., Caulet-Maugendre, S., Germain, N., Molet, S., Lagente, V., & Boichot, E.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2001
- Volume
- 193
- Issue
- 4
- Pages
- 538-545
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2021690302
- Cited by
- 145
- References
- 1
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.